Question 480
At fictional Westhaven Energy, a European privacy professional responsible for employee fleet systems is reviewing GDPR territorial scope, accountability and regulatory supervision during a controller-processor governance workshop (CIPPE-IV.B-120). The reported privacy issue is: A hospital launches systematic large-scale monitoring of vulnerable patients without considering a DPIA. Which ongoing control most directly reduces the risk of repeating this issue?
Explanation
Correct Answer
This recurring safeguard is to screen high-risk health monitoring at concept approval. It directly addresses the risk that a hospital launches systematic large-scale monitoring of vulnerable patients without considering a DPIA. The associated corrective decision is to assess whether the intended high-risk processing requires a data protection impact assessment; success is shown when the DPIA evaluates necessity, proportionality, risks and safeguards before launch.
Incorrect Answers
This option focuses on assess the specific Article 30(5) conditions and exceptions to the small-enterprise rule rather than the precise legal problem: a hospital launches systematic large-scale monitoring of vulnerable patients without considering a DPIA. This recurring safeguard is to screen high-risk health monitoring at concept approval.
“Scan test systems for unnecessary production personal data.” concerns another compliance assessment: build safer testing defaults using minimization, masking and authorized access. It would not by itself resolve the described concern: a hospital launches systematic large-scale monitoring of vulnerable patients without considering a DPIA. This recurring safeguard is to screen high-risk health monitoring at concept approval.
The compliance measure “Rehearse regulator inquiry handling during governance audits.” addresses establish accountable cooperation and record-retrieval processes for supervisory inquiries. The specific issue is that a hospital launches systematic large-scale monitoring of vulnerable patients without considering a DPIA; this recurring safeguard is to screen high-risk health monitoring at concept approval.